About Us: Leadership

Chief Executive Officer 

Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code Bio. He also serves as the Chairman of the Board of Genisphere, LLC, a Board Observer of Araris Biotech AG, and is a Venture Partner with 4BIO Capital. He has held leadership roles in both private and public biotechs, including a 25-year career with GlaxoSmithKline (GSK) Pharmaceuticals where he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management. Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a Certificate of Professional Development from the Wharton Business School at the University of Pennsylvania. He is a Certified Public Accountant, Certified Management Accountant, and Certified Licensing Professional.

Chief Scientific Officer 

Dave Anderson serves as Code Bio’s Chief Scientific Officer. He is responsible for guiding the long-term vision for research and discovery and for driving Code Bio’s overall scientific strategy in Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases. Dave leads efforts across research, discovery, translational medicine, regulatory strategy, and early development.

Prior to joining Code Bio, Dave served as Senior Vice President, Research at SwanBio Therapeutics directing translation of genetic therapies in development for the treatment of rare neurological diseases of the spinal cord. Prior to his role at SwanBio, Dave directed all preclinical research for the treatment of neurological diseases at Spark Therapeutics, Inc., where he oversaw development and growth of the central nervous system portfolio and team during his tenure.

​

Beyond his experience with SwanBio and Spark, Dave also co-founded two early-stage biotechnology companies, and previously served as faculty at Thomas Jefferson University. His expertise includes all aspects of experimental design and management with significant experience in molecular discovery and translation of basic research into preclinical animal models to support drug development.

Dave received a PhD in Molecular and Cell Biology from Thomas Jefferson University in 2005 and a B.Sc./Hons in Biomedical Sciences from Sheffield Hallam University in 1996.

Chief Operating Officer

Erin Brubaker serves as Code Bio’s Chief Operating Officer. She leads corporate strategy and governance, early commercial strategy, and oversees day-to-day operations of the company, with responsibility for ensuring optimal resource allocation while thoughtfully scaling the organization to accommodate future growth.

​

She has extensive and proven leadership experience in the biotechnology and pharmaceutical industry, which includes a 25-year career at GlaxoSmithKline  (GSK) where she held positions of increasing responsibility enterprise-wide across Commercial, Business Development, and R&D in the global pharmaceutical business. Erin has specific business experience in Gene Therapy and Biopharmaceuticals, as well as therapeutic expertise in Rare Diseases, Musculoskeletal, Metabolic, Immunology, Gastrointestinal, Urogenital, Cardiovascular, and Infectious Diseases. Her last role at GSK was Vice President, R&D Strategy and Operations, where she was responsible for managing scientific governance and other global-scale initiatives. Most recently, she served as Vice President, Corporate Development at Passage Bio, where she had an expanded role that included operational leadership in Portfolio Strategy, New Product Planning, and Corporate Governance.

​

Erin holds a Bachelor of Arts degree from Franklin & Marshall College. She also completed the Transformational Leadership for Executives program through Wharton Business School at the University of Pennsylvania, as well as professional certifications in Executive Coaching and Alliance Management.

Chief Financial Officer

Keith Dewedoff serves as Code Bio’s Chief Financial Officer. He oversees all accounting and finance functions and advises on strategic financing activities.

​

Keith brings more than 20 years of experience in the life science industry, ranging from biotech venture-backed start-ups to commercial publicly traded companies. Keith also serves as a CFO and Advisor for Danforth Advisors, an advisory firm focused on providing financial strategy to life science organizations. He previously served as CFO of Ceptur Therapeutics and more than 10 other privately held and public companies at various life cycle stages; managing finance, accounting, corporate development, and other corporate operational functions. Prior to Danforth, Keith was CFO of Kaizen Bioscience where he is still active on the board as Chair.

​

Keith earned a Bachelor of Science from Northeastern University and completed graduated work at Imperial College London and Oxford University.

Chief Platform Technologies Officer

Bob Getts serves as Chief Platform Technologies Officer and is a Co-Founder of Code Bio. Bob leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.

​

Bob possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.

​

Bob has a Ph.D. in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 U.S. and international patent applications.

Chief Business Officer

Lauren Kaskiel serves as Code Bio’s Chief Business Officer. She oversees business development, investor relations and intellectual property functions.

​

Lauren has more than 20 years of experience in the biotech and pharmaceutical industry. Prior to Code, she served as Head of Program and Alliance Management at Spark Therapeutics. During her time at Spark, Lauren also held roles in New Product Planning and Program Management, establishing and managing key strategic relationships on gene therapy programs with Pfizer and Novartis. Lauren served as a liaison with the Roche Group to support engagement and interactions during the acquisition of Spark in December of 2019 and contributed to defining the operating model and governance for Spark as Chief of Staff to the Executive Team. Previously, Lauren was at GlaxoSmithKline in research, operations, strategy, and alliance management roles. As part of GSK’s Worldwide Business Development team, Lauren managed over 20 alliances with biotech, diagnostic and venture partners.

​

Lauren holds a Bachelor of Science degree in Biotechnology with a Minor in Microbiology from Pennsylvania State University and an MBA with a concentration in Marketing from Drexel University. She has her Certificate of Achievement in Alliance Management (CA-AM) through the Association of Strategic Alliance Professionals (ASAP) and is a frequent guest lecturer at both Penn State and Drexel Universities.

Chief Technical Officer

Alex oversees the overall manufacturing strategy, technical development and chemistry, manufacturing, and controls (CMC) roadmap at Code Bio.

​

Alex has more than 20 years of experience in the biotech and pharmaceutical industry. Prior to Code, he served as Chief Technical Officer at BridgeBio Gene Therapy. During his time at BridgeBio, Alex developed the regulatory CMC strategy, led process and analytical development as well as external manufacturing for several clinical-stage AAV gene therapy programs. Alex also held the role of Chief Technical Officer at Istari Oncology, where he successfully negotiated Phase III comparability and control strategies with the FDA for the company’s glioblastoma monotherapy program. Dr. Tracy also served as Vice President of Pharmaceutical Development and Manufacturing at Enzyvant/Roivant Sciences, Head of Manufacturing Science & Technology at Hospira, a Pfizer Company, as well as Global Head of Manufacturing Science & Technology at Novartis Vaccines & Diagnostics.

​

Alex received a PhD in Biochemistry and Molecular Biology from University of Georgia, an M.S. in Chemistry at George Mason University, as well as a B.S. in Chemistry and English from The College of William and Mary. 

Head of Process Development and Preclinical Production

Lori Getts is the Head of Process Development and Preclinical Production, and a Co-Founder of Code Bio. Lori leads the process scale up, CMC, and preclinical development functions for all of our pipeline programs. She has 20+ years’ experience in the biotech industry, developing therapeutic drug delivery platforms for targeted therapeutics, as well as developing and commercializing reagents and research kits used in a variety of biological assays throughout the life sciences and diagnostic sectors. 

​

Lori was most recently the Vice President of Preclinical and Process Development at Genisphere, LLC where she played a pivotal role in the development of the 3DNA platform. She also directed the manufacture and QC of Genisphere’s entire reagents and research kit product line (over 135 products) including the OEM manufacture of the company’s flagship product, FlashTag®.

​

Lori is a co-author of many posters and papers as well as a co-inventor on several of the company’s patents and patent applications. She received her Ph.D. in Chemistry (Biochemistry focus) from Lehigh University and completed her Ph.D. thesis at Fox Chase Cancer Center where she used ovarian cancer model systems to study ovarian cancer etiology.

Head of Analytical Methods Development, Chemistry, Manufacturing, and Controls (CMC)

Matt Roberts is Code Bio’s Head of Analytical Methods Development, CMC. Matt’s focus is on building a state-of-the-art team responsible for developing fit-for-purpose analytical methods for characterization, in-process, stability, and Quality Control (QC) release testing of Code Bio’s innovative gene delivery technology and product pipeline.

Matt has more than 10 years of experience in the pharmaceutical industry. He started his industry career at GlaxoSmithKline as an R&D Biopharmaceutical Technical Development Program Associate (now the Future Leaders Program). Matt’s responsibilities in subsequent roles at GSK spanned analytical methods development for the assessment of biopharmaceutical and cell and gene therapies, leading teams of assay developers, and establishing analytical testing strategies for assets ranging from candidate selection to launched product. Prior to joining Code, Matt served as GSK’s Director of Cell & Gene Therapy Analytical Development, where he managed a team of US- and UK-based group leaders to develop, transfer, and validate analytical methods in support of GSK’s product pipeline.

​

Matt holds a PhD and MPhil in Molecular Biophysics and Biochemistry from Yale University and a Bachelor of Science degree in Biochemistry from the University of Delaware.

Head of Project Management

Amanda Skoumbourdis serves as Code Bio’s Head of Project Management. She oversees PMO activities and is responsible for planning and organization of Code Bio’s research projects through all stages.

​

Prior to joining Code Bio, Amanda was Senior Director, Program Management for Gyroscope Therapeutics, where she led the organization’s second asset to IND enabling studies. Additionally, Amanda was the business partner to the SVP of Technical Operations, supporting device development and alliance management for the manufacturing team. Prior to Gyroscope, Amanda project managed liver-directed assets at all stages and created a governance committee for the CSO at Spark Therapeutics. She brings over 20 years of combined experience in discovery and translational research and integrated program management in biotech and pharma and has held project management roles of increasing responsibility for over 10 years. Amanda began her pharmaceutical career at Sandoz, Inc. a Novartis Company, where she served as the first scientific advisor for the intellectual property group.

​

Amanda received a PhD in Synthetic Organic Chemistry from Pennsylvania State University and a Bachelor of Science in Chemistry from the College of New Jersey. She was awarded an IRTA Postdoctoral Fellowship at The National Institutes of Health in Bioorganic and Medicinal Chemistry. She was one of the first postdoctoral fellows assigned to the NCATS Chemical Genomics Center (NCGC), formerly known as the NIH Chemical Genomics Center.

Head of Translational Medicine

Latha Vasireddy serves as Code Bio’s Head of Translational Medicine. She leads the translational development team to identify novel therapeutic strategies for delivering genetic payloads in multiple rare disease programs. 

Latha has more than 12 years of experience in developing AAV-mediated gene therapy candidates for rare neurodegenerative diseases. Prior to joining Code Bio, she worked as a Director of Translational Toxicology at SwanBio Therapeutics and directed AAV-mediated gene therapies in neurological diseases of the spinal cord. At SwanBio, Latha led the organization’s lead candidate from the earliest preclinical stage through IND. Previously, Latha served as a Director of Translational Sciences at the Center for Advanced Retinal & Ocular Therapeutics (CAROT) at the University of Pennsylvania where she was involved in the clinical development of multiple gene therapy products for retinal degenerative disease. 

Latha received a Ph.D. in Biochemistry from Osmania University, India, and trained in molecular mechanisms of retinal degenerative diseases during her post-doctoral fellowship at the Kellogg Eye Center at the University of Michigan. She also earned her Certificate in Translational Sciences and Regulatory Affairs from the University of Pennsylvania.